Groupe d'Etude en Oncologie du Quebec

Title	The predictive value of coexisting TMPRSS2-ERG gene fusion and PTEN deletion in prostate cancer patients with biochemical failure status post salvage or radical radiation therapy
Protocole ID	PCS VIII
ClinicalTrials.gov ID	NCT02573636
Cancer Type(s)	Prostate
Phase	Other
Stage
Study Type
Drug
Institution	CISSS DE LAVAL HOPITAL DE LA CITE-DE-LA-SANTE 1755 boul. René-Laennec, Laval, QC, H7M 3L9
City	Laval
Principal Investigator	Dr. Levon Igidbashian
Coordinator	Solange Tremblay 450-668-1010 poste 23603
Status	Recruiting
Activation Date	26-07-2016
Eligibility Criteria	Patients with adenocarcinoma of the prostate, status post-radical radiation therapy or salvage radiation therapy, who have biochemical failure (rising PSA) or not (matched control group), and meets one of the following criteria at the time of the original diagnosis: T3a + PSA > 20 Gleason 8 or higher Karnofsky performance status ≥ 70. Signed study-specific informed consent
Exclusion Criteria

Groupe d'étude en oncologie du Québec